FDA approves Bracco's ProHance for use in kids

By AuntMinnie.com staff writers

December 23, 2020 -- The U.S. Food and Drug Administration (FDA) has approved the use of the ProHance MRI contrast agent by Bracco Diagnostics for use in MRI scans of pediatric patients.

ProHance (gadoteridol) is a gadolinium-based contrast agent now indicated for intravenous use with MRI in patients less than 2 years old, including full-term newborns. The agent, which was previously approved for patients older than 2, visualizes areas with disrupted blood brain barriers and/or abnormal vascularity throughout the brain, spine, and associated tissues.

Copyright © 2020 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking